drugset / Trial / NCT01070862
Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study was to evaluate efficacy and tolerability of Thalidomide in first-line treatment of multiple myeloma as induction treatment in young patients, with Dexamethasone before autotransplant, and in elderly patients in combination with conventional chemotherapy and as consolidation/maintenance therapy in young and elderly patients at plateau-phase.
Timeline
- Start
- 2003-05
- Primary completion
- —
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 9 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 6 mg/m2 | Oral |
| Subject | Thalidomide | Other / unclassified | 200 mg | — |
| Comparator | Vincristine | Small molecule | 0.4 mg | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
Indications
No indication recorded.